A Study to Assess the Safety, Tolerability and Clinical Activity of TD−1211 in Patients With Opioid-Induced Constipation



Status:Completed
Conditions:Constipation
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - 65
Updated:1/30/2019
Start Date:May 2011
End Date:June 2012

Use our guide to learn which trials are right for you!

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Clinical Activity of TD−1211 in Subjects With Opioid-Induced Constipation

A dose-escalation study to assess the safety, tolerability and clinical activity of TD−1211
in patients with opioid-induced constipation.


Inclusion Criteria:

- Males and females between 18 and 65 years of age, inclusive

- Subjects with documented OIC on stable opioid regimen

- Willingness to stop all laxatives throughout run-in and treatment period

Exclusion Criteria:

- Any clinically significant findings in subjects with OIC

- Have participated in another clinical trial of an investigational drug 30 days prior
to screening

- History of chronic constipation prior to opioid therapy in OIC subjects

- Active medical disorders associated with diarrhea or intermittent loose stools in OIC
subjects
We found this trial at
1
site
Salt Lake City, Utah 84106
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials